Tackling the neurological manifestations in Wilson’s disease – currently available treatment options

References

• European Association For The Study of The Liver Disease.EASL Clinical Practice Guidelines: Wilson’s Disease.J Hepatol.2012;563:671–685.
   PubMed Web of Science ®Google Scholar
• Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428–1455.
   PubMed Web of Science ®Google Scholar
• Socha P, Janczyk W, Dhawan A, et al. Wilson’s Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(2):334–344.
   PubMed Web of Science ®Google Scholar
• Nagral A, Sarma MS, Matthai J, et al. Wilson’s Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. J Clin Exp Hepatol. 2019;9(1):74–79. doi: 10.1016/j.jceh.2018.08.009
   PubMed Web of Science ®Google Scholar
• Yuan XZ, Yang RM, Wang XP. Management Perspective of Wilson’s Disease: Early Diagnosis and Individualized Therapy. Curr Neuropharmacol. 2021;19(4):465–485. doi: 10.2174/1570159X18666200429233517
   PubMed Web of Science ®Google Scholar
• Dong Y, Wu ZY. Challenges and suggestions for precise diagnosis and treatment of Wilson’s disease. World J Pediatr. 2021;17(6):561–565. doi: 10.1007/s12519-021-00475-4
   PubMed Web of Science ®Google Scholar
• Xie JJ, Wu ZY. Wilson’s disease in China. Neurosci Bull. 2017;33(3):323–330. doi: 10.1007/s12264-017-0107-4
   PubMed Web of Science ®Google Scholar
• Chinese Society of Neurogenetics. Chinese guidelines for diagnosis and treatment of Wilson’s disease 2021. Chin J Neurol. 2021;54:310–319.
   Google Scholar
• Chen C, Li WJ, You ZF, et al. Current drug managements of Wilson’s disease: from west to east. Curr Neuropharmacol. 2016;14(4):322–325. doi: 10.2174/1570159X14666151130222427
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Litwin T. Wilson disease – currently used anticopper therapy. Handb Clin Neurol. 2017;142:181–191. 6. Schilsky ML. Long-term outcome for Wilson disease: 85% good. Clin. Gastroenterol. Hepatol 2014; 12: 690-1.
   PubMedGoogle Scholar
• Schilsky ML. Long-term outcome for Wilson disease: 85% good. Clin Gastroenterol Hepatol. 2014;12(4):690–691. doi: 10.1016/j.cgh.2013.11.009
   PubMed Web of Science ®Google Scholar
• Litwin T, Dusek P, Czlonkowska A. Neurological manifestations in Wilson’s disease – possible treatment options for symptoms. Expert Opin Orphan Drugs. 2016;4(7):719–728. doi: 10.1080/21678707.2016.1188003
   Web of Science ®Google Scholar
• Antos A, Członkowska A, Smolinski L, et al. Early neurological deterioration in Wilson’s disease: a systematic literature review and meta-analysis. Neurol Sci. 2023;44(10): doi: 10.1007/s10072-023-06895-6
   PubMed Web of Science ®Google Scholar
• Stankovic I, Jovanovic C, Vitkovic J, et al. Long-term outcome of patients with neurological form of Wilson’s disease compliant to the de-coppering treatment. J Neurol. 2023;270(7):3492–3498. doi: 10.1007/s00415-023-11681-7
   PubMed Web of Science ®Google Scholar
• Heffter H, Tezayak O, Rosenthal D. Long-term outcome of neurological Wilson’s disease. Parkinsonism Related Disord. 2018;29:48–53. doi: 10.1016/j.parkreldis.2018.01.007
   Google Scholar
• Litwin T, Antos A, Bembenek J, et al. Copper deficiency as Wilson’s disease overtreatment: a systematic review. Diagnostics. 2023;13(14):2424. doi: 10.3390/diagnostics13142424
   Web of Science ®Google Scholar
• Antos A, Czlonkowska A, Bembenek J, et al. D-Penicillamine-Induced Myasthenia Gravis—A Probable Complication of Wilson’s Disease Treatment—A Case Report and Systematic Review of the Literature. Life. 2023;13(8):1715. doi: 10.3390/life13081715
   PubMedGoogle Scholar
• Bakheit AMO. Management of neurogenic dysphagia. Postgrad Med J. 2001;77(913):694–699. doi: 10.1136/pmj.77.913.694
   PubMed Web of Science ®Google Scholar
• Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Sci. 2014;1315(1):81–85. doi: 10.1111/nyas.12437
   PubMedGoogle Scholar
• Chou KL, Evatt M, Hinson V, et al. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007;22(16):2306–2313. doi: 10.1002/mds.21646
   PubMed Web of Science ®Google Scholar
• Crary MA, Carnaby-Mann GD, Faunce A. Electrical stimulation therapy for dysphagia: descriptive results of two surveys. Dysphagia. 2007;22(3):165–173. doi: 10.1007/s00455-006-9068-x
   PubMed Web of Science ®Google Scholar
• Dwarakanath S, Zafar A, Yadav R, et al. Does lesioning surgery have a role in the management of multietiological tremor in the era of Deep Brain Stimulation?. Clin Neurol Neurosur. 2014;125:131–136. doi: 10.1016/j.clineuro.2014.07.016
   PubMed Web of Science ®Google Scholar
• Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153–160. doi: 10.1007/s13311-013-0244-z
   PubMed Web of Science ®Google Scholar
• Gage H, Storey L. Rehabilitation for Parkinson’s disease: a systematic review of available evidence. Clin Rehabil. 2004;18(5):463–482. doi: 10.1191/0269215504cr764oa
   PubMed Web of Science ®Google Scholar
• Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–640. doi: 10.1002/mds.21922
   PubMed Web of Science ®Google Scholar
• Lal D, Hotaling AJ. Drooling. Curr Opin in Otolaryngol Head Neck Surg. 2006;14(6):381–386. doi: 10.1097/MOO.0b013e328011014a
   PubMedGoogle Scholar
• Loser C, Aschl G, Hebuterne X, et al. ESPEN guidelines on artificial enteral nutrition – Percutaneous endoscopic gastrostomy (PEG). Clin Nutr. 2005;24(5):848–861.
   PubMed Web of Science ®Google Scholar
• Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol. 2011;31(1):65–77. doi: 10.1055/s-0031-1271312
   PubMed Web of Science ®Google Scholar
• Schneider SA, Deuschl G. The treatment of tremor. Neurotherapeutics. 2014;11(1):128–138. doi: 10.1007/s13311-013-0230-5
   PubMed Web of Science ®Google Scholar
• Teive HA, Munhoz RP, Souza MM, et al. Status dystonicus study of five cases. Arq Neuropsiquiatr. 2005;63(1):26–29. doi: 10.1590/S0004-282X2005000100005
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139–152. doi: 10.1007/s13311-013-0231-4
   PubMed Web of Science ®Google Scholar
• Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia. 1988;3(2):73–78. doi: 10.1007/BF02412423
   PubMedGoogle Scholar
• Woitalla D, Goetze O. Treatment approaches of gastrointestinal dysfunction in Parkinson’s disease, therapeutical options and future perspectives. J Neurol Sci. 2011;310(1–2):152–158. doi: 10.1016/j.jns.2011.06.050
   PubMed Web of Science ®Google Scholar
• Lorincz MT. Neurologic Wilson’s disease. Ann N Y Sci. 2010;1184(1):173–187. doi: 10.1111/j.1749-6632.2009.05109.x
   PubMedGoogle Scholar
• Svetel M, Kozic D, Stefanova E, et al. Dystonia in Wilson’s disease. Mov Disord. 2001;16(4):719–723. doi: 10.1002/mds.1118
   PubMed Web of Science ®Google Scholar
• Trocello JM, Osmani K, Pernon M, et al. Hypersialorrhea in Wilson’s disease. Dysphagia. 2015;30(5):489–495. doi: 10.1007/s00455-015-9627-0
   PubMed Web of Science ®Google Scholar
• Holscher S, Leinweber B, Hefter H, et al. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64(2):83–87. doi: 10.1159/000316066
   PubMed Web of Science ®Google Scholar
• Chakor RT, Bharote H, Eklare N, et al. Unilateral rubral tremors in Wilson’s disease treated with dimercaprol. Ann Indian Acad Neurol. 2015;18(1):115–116. doi: 10.4103/0972-2327.144286
   PubMed Web of Science ®Google Scholar
• Pal PK, Sinha S, Pillai S, et al. Successful treatment of tremor in Wilson’s disease by thalamotomy: A case report. Mov Disord. 2007;22(15):2287–2290. doi: 10.1002/mds.21750
   PubMed Web of Science ®Google Scholar
• Paliwal VK, Gupta PK, Pradhan S. Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease. Neurol India. 2010;58(5):761–763. doi: 10.4103/0028-3886.72184
   PubMed Web of Science ®Google Scholar
• Burke JF, Dayalu P, Nan B, et al. Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord. 2011;17(7):551–556. doi: 10.1016/j.parkreldis.2011.05.002
   PubMed Web of Science ®Google Scholar
• Teive HA, Kluppel LE, Munhoz RP, et al. Jaw-opening oromandibular dystonia secondary to Wilson’s Disease treated with botulinum toxin type A. Arq Neuropsiquiatr. 2012;70(6):407–409. doi: 10.1590/S0004-282X2012000600005
   PubMed Web of Science ®Google Scholar
• Litwin T, Chabik G, Czlonkowska A. Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurol Neurochir Pol. 2013;47(5):502–506. doi: 10.5114/ninp.2013.38230
   PubMed Web of Science ®Google Scholar
• Litwin T, Gromadzka G, Czlonkowska A. Neurological presentation of Wilson’s disease in a patient after liver transplantation. Mov Disord. 2008;23(5):743–745. doi: 10.1002/mds.21913
   PubMed Web of Science ®Google Scholar
• Barbeau A, Friesen H. Treatment of Wilson’s disease with L-dopa after failure with penicillamine. Lancet. 1970;1(7657):1180–1182. doi: 10.1016/S0140-6736(70)91259-6
   PubMed Web of Science ®Google Scholar
• Gelmers HJ, Troost J, Willemse J. Wilson’s disease: modification by L-DOPA. Neuropadiatrie. 1973;4(4):453–457. doi: 10.1055/s-0028-1091761
   PubMedGoogle Scholar
• Gondim FA, Araujo DF, Oliveira IS, et al. Levodopa-responsive Parkinsonism and small fiber dysfunction in patients with Wilson’s disease. MOV DISORD. 2013;28:S351–S2. doi: 10.1016/j.jns.2013.07.2448
   Web of Science ®Google Scholar
• Berio A, Vento R, Di Stefano A. Favorable results with an association of L-dopa and amantadine added to penicillamine in the treatment of Wilson’s disease. Minerva Pediatr. 1973;25(18):807–813.
   PubMedGoogle Scholar
• Frankel JP, Hughes A, Lees AJ, et al. Use of apomorphine to test for dopamine responsiveness in Wilson’s disease. Lancet. 1989;2(8666):801–802. doi: 10.1016/S0140-6736(89)90862-3
   PubMed Web of Science ®Google Scholar
• Morgan JP, Preziosi TJ, Bianchine JR. Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson’s disease. Lancet. 1970;2(7674):659. doi: 10.1016/S0140-6736(70)91422-4
   PubMed Web of Science ®Google Scholar
• Micheli F, Tschopp L, Cerosimo MG. Oxcarbamazepine-responsive paroxysmal kinesigenic dyskinesia in Wilson disease. Clin Neuropharm. 2011;34(6):262–264. doi: 10.1097/WNF.0b013e3182348964
   PubMed Web of Science ®Google Scholar
• Hirabayashi S, Kanda H, Tsuno T, et al. Effects of high-dosage trihexyphenidyl on symptomatic dystonia in a case of Wilson disease. No To Hattatsu. 1985;17(6):571–576.
   PubMedGoogle Scholar
• Sidiropoulos C, Hutchison W, Mestre T, et al. Bilateral pallidal stimulation for Wilson’s disease. Mov Disord. 2013;28(9):1292–1295. doi: 10.1002/mds.25446
   PubMed Web of Science ®Google Scholar
• Hedera P. Treatment of Wilson’s disease motor complications with deep brain stimulation. Ann N Y Acad Sci. 2014;1315(1):16–23. doi: 10.1111/nyas.12372
   PubMedGoogle Scholar
• Barthel H, Hermann W, Kluge R, et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. Am J Neuroradiol. 2003;23:234–238.
   Google Scholar
• Litwin T, Gromadzka G, Samochowiec J, et al. Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease. JIMD Rep. 2013;8:73–80.
   PubMedGoogle Scholar
• Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson’s Diseases. J Neurol Sci. 2015;355(1–2):162–167. doi: 10.1016/j.jns.2015.06.010
   PubMed Web of Science ®Google Scholar
• Hamada Y. Objective data assessment (ODA) methods as nutritional assessments tools. J Med Invest. 2015;62(3–4):119–122. doi: 10.2152/jmi.62.119
   PubMedGoogle Scholar
• Lee SY, Yang HE, Yang HS, et al. Neuromuscular electrical stimulation therapy for dysphagia caused by Wilson’s disease. Ann Rehabil Med. 2012;36(3):409–413. doi: 10.5535/arm.2012.36.3.409
   PubMedGoogle Scholar
• Da Silva-Junor FP, Carrasco AEAB, Da Silva Mendes AM, et al. Swallowing dysfunction in Wilson’s disease: a scintigraphic study. Neurogstroenterol Motil. 2008;20(4):285–290. doi: 10.1111/j.1365-2982.2007.01036.x
   PubMed Web of Science ®Google Scholar
• Berry WR, Darley FL, Aronson AE. Dysarthria in Wilson’s disease. J Speech Hear Res. 1974;17(2):169–183. doi: 10.1044/jshr.1702.169
   PubMedGoogle Scholar
• Walshe JM. Yealland M.Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry. 1992;55(8):692–696. doi: 10.1136/jnnp.55.8.692
   PubMed Web of Science ®Google Scholar
• Friedman A, Potulska A. Quantitative assessment of parkinsonian silorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord. 2001;7(4):329–332. doi: 10.1016/S1353-8020(00)00073-0
   PubMed Web of Science ®Google Scholar
• Ertan E, Gurvit HI, hanagasi HH, et al. Intensive voice treatment (the Lee Silverman Voice Tretament[LVST LOUD]) for individuals with Wilson’s disease and adult cerebral palsy: two case reports. Logoped Phoniatr Vocol. 2022;47(4):262–270. doi: 10.1080/14015439.2021.1951348
   PubMed Web of Science ®Google Scholar
• Maciel R, Portela DC, Souza GX, et al. Improvement of „wing-beating” tremor in Wilson’s disease with high dose of zolpidem: a case report. Mov Disord in Clin Pract. 2019;6(7):608–609. doi: 10.1002/mdc3.12815
   PubMed Web of Science ®Google Scholar
• Poujois A, Pernon M, Trocello JM, et al. Dystonic dysarthria in Wilson disease: efficacy of zolpidem. Front Neurol. 2017;8:559. doi: 10.3389/fneur.2017.00559
   PubMed Web of Science ®Google Scholar
• Lozeron P, Poujois A, Meppiel E, et al. Inhibitory rTMS applied on somatosensory cortex in Wilson’s disease patient with hand dystonia. J Neural Transm (Vienna). 2017;124(10):1161–1170. doi: 10.1007/s00702-017-1756-1
   PubMed Web of Science ®Google Scholar
• Hao W, Wei T, Yang W, et al. Effects of high-frequency repetitive transcranial magnetic stimulation on upper limb dystonia in patients with Wilson’s disease; a randomized controlled trial. Front Neurol. 2021;12:783365. doi: 10.3389/fneur.2021.783365
   PubMed Web of Science ®Google Scholar
• Newland DP, Novakovic D, Richards AL. Voice Tremor and Botulinum Neurotoxin Therapy: A Contemporary Review. Toxins (Basel). 2022;14(11):773. doi: 10.3390/toxins14110773
   PubMed Web of Science ®Google Scholar
• Brewer G, Fink J, Hedera P. Diagnosis and treatment of Wilson’s disease. Semin Neurol. 1999;19(3):261–269. doi: 10.1055/s-2008-1040842
   PubMed Web of Science ®Google Scholar
• Bruha R, Marecek Z, Pospilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int. 2011;31(1):83–91. doi: 10.1111/j.1478-3231.2010.02354.x
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease cause of mortality in 164 patients during 1992-2003 observation period. J Neurol. 2005;252(6):698–703. doi: 10.1007/s00415-005-0720-4
   PubMed Web of Science ®Google Scholar
• Hefter H, Samadzadeh S. Effective treatment of neurological symptoms with normal doses of botulinum neurotoxin in Wilson’s disease: six cases and literature review. Toxins (Basel). 2021;13(4):241. doi: 10.3390/toxins13040241
   PubMed Web of Science ®Google Scholar
• Cao Z, Rao R, Wu T, et al. Botulinum toxin type A treatment of four cases of Wilson’s disease with lower limb dystonia; a prospective study. Toxicon. 2023;221:106959. doi: 10.1016/j.toxicon.2022.106959
   PubMed Web of Science ®Google Scholar
• Roca MCU, Micheli F, Viotti R. Cannabis sativa and dystonia secondary to Wilson’s disease. Mov Disord. 2005;20(1):113–115.
   PubMed Web of Science ®Google Scholar
• Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson’s disease: The burden of neurological and psychiatric disorders. Liver Transpl. 2005;11(9):1056–1063. doi: 10.1002/lt.20486
   PubMed Web of Science ®Google Scholar
• Wang XH, Cheng F, Zhang F, et al. Living related liver transplantation for Wilson’s disease. Transplant Proc. 2001;18(6):651–656. doi: 10.1111/j.1432-2277.2004.00074.x
   Google Scholar
• Weiss KH, Schaefer M, Gotthardt DN, et al. Outcome and development of symptoms after orthopic liver transplantation for Wilson disease. Clin Transplant. 2013;27(6):914–922. doi: 10.1111/ctr.12259
   PubMed Web of Science ®Google Scholar
• Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson’s disease: experience in France. J Hepatol. 2014;60(3):579–589. doi: 10.1016/j.jhep.2013.10.025
   PubMed Web of Science ®Google Scholar
• Catana AM, Medici V. Liver transplantation for Wilson’s disease. World J Hepatol. 2012;4(1):5–10. doi: 10.4254/wjh.v4.i1.5
   PubMedGoogle Scholar
• Stracciari A, Tempestini A, Borghi A, et al. Effect of liver transplantation on neurological manifestations in Wilson’s disease. Arch Neurol. 2000;57(3):384–386. doi: 10.1001/archneur.57.3.384
   PubMedGoogle Scholar
• Litwin T, Dziezyc K, Poniatowska R, et al. Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurol Neurochir Pol. 2013;47(4):393–397. doi: 10.5114/ninp.2013.36763
   PubMed Web of Science ®Google Scholar
• Yagci MA, Tardu A, Karagul S, et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease. Transplant Proc. 2015;47(5):1469–1473. doi: 10.1016/j.transproceed.2015.04.017
   PubMed Web of Science ®Google Scholar
• Geissler I, Heinemann K, Rohm S, et al. Liver transplantation for hepatic and neurological Wilson’s disease. Transplant Proc. 2003;35(4):1445–1446. doi: 10.1016/S0041-1345(03)00464-0
   PubMed Web of Science ®Google Scholar
• Bax RT, Hassler A, Luck W, et al. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology. 1998;51(3):863–865.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Gothardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson’s disease. Gastroenterology. 2011;140(4):1189–1198. doi: 10.1053/j.gastro.2010.12.034
   PubMed Web of Science ®Google Scholar
• Litwin T, Bembenek J, Antos A, et al. Liver transplantation as a treatment for Wilson’s disease with neurological presentation; a systematic literaturę review. Acta Neurol Belg. 2022;122(2):505–518. doi: 10.1007/s13760-022-01872-w
   PubMed Web of Science ®Google Scholar
• Poujois A, Sobesky R, Meissner WG, et al. Liver transplantation as a rescue therapy for severe neurologic forms of Wilson’s disease. Neurology. 2020;94(21):1–e14. doi: 10.1212/WNL.0000000000009474
   Web of Science ®Google Scholar
• Xu WQ, Wang RM, Dong Y, et al. Emerging neurological symptoms after liver transplantation: A 6-year follow-up of an adolescent patient with Wilson’s disease. CNS Neurosci Ther. 2022;28(5):788–791. doi: 10.1111/cns.13798
   PubMed Web of Science ®Google Scholar
• Low HL, Alexander SK, Misbahuddin A, et al. Posterior subthalamic area deep brain stimulation for treatment of tremor and dystonia in Wilson’s disease. Brain Stimulation. 2019;12(5):1304–1306. doi: 10.1016/j.brs.2019.05.014
   PubMed Web of Science ®Google Scholar
• Dhar D, Halla W, Karnble N, et al. Surgical outcomes in rare movement disorders; a report of seventeen patients from India and review of litearture. Tremor and other hyperkinetic movements. 2022;12(1):1–21. doi: 10.5334/tohm.693
   Google Scholar
• Mohr I, Pfeiffenberger J, Eker E, et al. Neurological worsening in Wilson disease – clinical classification and outcome.J Hepatol. J hepatol. 2023;79(2):321–328. doi: 10.1016/j.jhep.2023.04.007
   PubMed Web of Science ®Google Scholar
• Litwin T, Członkowska A, Smolinski L. Early neurological worsening in Wilson’s disease: the need for an evidence-based definitione. J Hepatol. 2023. doi: 10.1016/j.jhep.2023.06.009
   PubMedGoogle Scholar
• Kalita J, Tripathi A, Jadhav M, et al. A study of dopaminergic pathway in neurologic Wilson disease with movemeent disorder. Mol Neurobiol. 2023;60(6):3496–3506. doi: 10.1007/s12035-023-03276-0
   PubMedGoogle Scholar
• Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. doi: 10.1038/s41572-018-0018-3
   PubMedGoogle Scholar
• Antos A, Litwin T, Przybylkowski A, et al. D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilson’s disease. Neurol Neurochir Pol. 2020;55(6):595–597. doi: 10.5603/PJNNS.a2021.0080
   Web of Science ®Google Scholar
• Samanci B, Sahin E, Tufekcioglu Z, et al. Neurological features and outcomes of Wilson’s disease: a single-center experience. Neurol Sci. 2021;42(9):3829–3834. doi: 10.1007/s10072-020-05013-0
   PubMed Web of Science ®Google Scholar
• Dubbioso R, ranucci G, esposito M, et al. Subclinical neurological involvement does not develop if Wilson’s disease is terated early. Parkinsonism and Related Disorders. 2016;24:15–19.
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Litwin T, Karlinski M, et al. D-penicillamine versus zinc sulfate s first-line therapy for Wilson’s Diseases. Eur J Neurol. 2014;21(4):599–606. doi: 10.1111/ene.12348
   PubMed Web of Science ®Google Scholar
• Beinhardt S, Leiss W, Stattermayer AF, et al. Long term outcomes of patients with Wilson disease in large Austrian cohort. Clin Gastroenetrol Hepatol. 2014;12(4):683–689. doi: 10.1016/j.cgh.2013.09.025
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson’s disease?. J Am Coll Nutr. 1993;12(5):527–530). doi: 10.1080/07315724.1993.10718347
   PubMed Web of Science ®Google Scholar
• Litwin T, Dzieżyc K, Czlonkowska A. Wilson disease—treatment perspectives. Ann Transl Med. 2019;7(S2):S68. doi: 10.21037/atm.2018.12.09
   PubMedGoogle Scholar
• Ziemssen T, Smolinski L, Czlonkowska A, et al. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease. Acta Neurol Belg. 2023;123(3):917–925. doi: 10.1007/s13760-022-02091-z
   PubMed Web of Science ®Google Scholar
• Antos A, Członkowska A, Bembenek J, et al. Blood based biomarkers of central nervous system involvement in Wilson’s disease. Diagnostics. 2023;13(9):1554. doi: 10.3390/diagnostics13091554
   Web of Science ®Google Scholar
• Redzia-Ogrodnik B, Czlonkowska A, Antos A, et al. Pathognomonic neuroradiological signs in Wilson’s disease – Truth or myth?. Parkinsonism Related Disord. 2023;107:105247. doi: 10.1016/j.parkreldis.2022.105247
   PubMed Web of Science ®Google Scholar
• Dusek P, Smolinski L, Redzia-Ogrodnik B, et al. Semiquantitative scale for assessing brain MRI abnormailities in Wilson disease: a validation study. Mov Disord. 2020;35(6):994–1001. doi: 10.1002/mds.28018
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie D, Li Y, et al. Evaluation of efficacy and safety of gandouling plus sodium dimercaptosulphonate in treatment of patients with neurological Wilson’s disease from China. J Traditional Chin Med. 2018;38(5):781–786. doi: 10.1016/S0254-6272(18)30919-1
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang LL, Li LY, et al. Gandouling Tablets Inhibit Excessive Mitophagy in Toxic Milk (TX) Model Mouse of Wilson Disease via Pink1/Parkin Pathway. Evid Based Complement Alternat Med. 2020;2020:3183714. doi: 10.1155/2020/3183714
   PubMed Web of Science ®Google Scholar
• Chevalier K, Rahli D, de Veyrac L, et al. Quality of life and depression in Wilson’s disease: a large prospective cross-sectional study. Orphanet J Rare Dis. 2023;18(1):168. doi: 10.1186/s13023-023-02777-4
   PubMed Web of Science ®Google Scholar